Baxdrostat, a novel aldosterone synthase inhibitor, demonstrated a highly clinically meaningful reduction in 24-hour ...
Aldosterone sends sodium and water into the bloodstream, which can increase your blood volume and blood pressure. Besides the ...
Topline data were announced from a phase 3 trial evaluating baxdrostat in patients with treatment-resistant hypertension.
A new pill called baxdrostat may offer hope for people whose blood pressure stays high even after taking standard medications ...
The NHS is warning that during this season, it might be easy to mistake flu symptoms for those of a rare health condition.
In top-line results, the phase III trial demonstrated a “highly clinically meaningful reduction” in 24-hour systolic BP.
healthdigest.com on MSN
A New Drug May Be The Key To Lowering Blood Pressure In Those With Chronic Kidney Disease
According to recent research, the drug, while still in its trial phases, has shown potential in inhibiting hormones that ...
AstraZeneca (AZN) stock is in focus as its blood pressure drug baxdrostat succeeds in a Phase 3 trial for patients with ...
11d
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback